This is a human IgG1 monoclonal antibody using the same sequences as the therapeutic antibody canakinumab. It functions as an interleukin-1β (IL1β) antagonist employed in the treatment of periodic fever syndromes such as cryopyrin-associated periodic syndromes (CAPS) and familial mediterranean fever (FMF), as well as active systemic juvenile idiopathic arthritis (SJIA). Canakinumab specifically binds to human IL1β, effectively neutralizing its inflammatory activity by obstructing its interaction with IL1 receptors. Importantly, it exhibits no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha. In inflammatory diseases involving CAPS, IL1β is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL1β, which is up-regulated by mutations in cryopyrin’s gene, NLRP-3.